心房颤动合并射血分数降低心衰的治疗
心房颤动(AF)与射血分数降低的心力衰竭(HFrEF)常共存并相互加重,增加卒中、心衰住院和全因死亡风险,尤其在AF发病后早期。本文深度综述现有随机与观察性试验数据,讨论HFrEF合并AF的治疗证据、需进一步研究领域,并提出个体化治疗策略建议。
要点
- AF与HFrEF共存增加卒中、心衰住院和全因死亡风险,尤其在AF发病后早期。
- HFrEF的指南导向药物治疗重要,但AF合并HFrEF的最佳治疗尚无明确共识。
- 本文综述现有证据,聚焦需进一步研究领域,并提出个体化治疗策略建议。
核心结论
- AF与HFrEF常共存并相互加重,增加卒中、心衰住院和全因死亡风险,尤其在AF临床发病后早期。
- HFrEF的指南导向药物治疗重要,但AF合并HFrEF的最佳治疗尚无明确共识。
研究设计与样本
- 本文为深度综述,讨论AF合并HFrEF治疗的现有数据,聚焦需进一步研究领域,检查随机和观察性临床试验的临床意义,并提出个体化治疗策略建议。
主要发现
- 基于人群的研究表明,AF与HFrEF共存增加卒中、心衰住院和全因死亡风险,尤其在AF临床发病后早期。
临床怎么用
- HFrEF的指南导向药物治疗重要;AF合并HFrEF的治疗需根据现有随机和观察性试验数据个体化制定。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) frequently coexist, and each complicates the course and treatment of the other. Recent population-based studies have demonstrated that the 2 conditions together increase the risk of stroke, heart failure hospitalization, and all-cause mortality, especially soon after the clinical onset of AF. Guideline-directed pharmacological therapy for HFrEF is important; however, although there are various treatment modalities for AF, there is no clear consensus on how best to treat AF with concomitant HFrEF. This in-depth review discusses the available data for the treatment of AF in the setting of HFrEF, focuses on areas where more investigation is necessary, examines the clinical implications of randomized and observational clinical trials, and presents suggestions for individualized treatment strategies for specific patient groups.
引用
- Verma A, Kalman JM, Callans DJ, et al. Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction. Circulation. 2017. PMID: 28416525. doi:10.1161/CIRCULATIONAHA.116.026054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。